909849-96-3

Basic information

• Product Name: Montelukast Sulfoxide (Mixture of diastereomers)
• Synonyms: 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfinyl]methyl]-cyclopropaneacetic Aci;Montelukast Sulfoxide (Mixture of diastereomers);1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfinyl]methyl]-cyclopropaneacetic Acid;Montelukast Sulfoxide;Montelukast M2;Montelukast Sulfoxide IMpurity-A;Montelukast EP IMpurity C;Montelukast Sulfoxide (Mixtuture of DiastereoMers)
• CAS NO: 909849-96-3
• Molecular Formula: C35H36ClNO4S
• Molecular Weight: 602.191
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 909849-96-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 95-97°C
• Boiling Point: 818.5°C at 760 mmHg
• Flash Point: 448.8°C
• Appearance: /
• Density: 1.319
• Vapor Pressure: 2.44E-28mmHg at 25°C
• Refractive Index: 1.69
• Storage Temp.: Amber Vial, -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Light Sensitive
• CAS DataBase Reference: Montelukast Sulfoxide (Mixture of diastereomers)(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast Sulfoxide (Mixture of diastereomers)(909849-96-3)
• EPA Substance Registry System: Montelukast Sulfoxide (Mixture of diastereomers)(909849-96-3)

Safety Data

• Hazardous Substances Data: 909849-96-3(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Solid

Uses

Montelukast Sulfoxide (Montelukast EP Impurity C; Montelukast USP Related Compound A; Montelukast Sulfoxid) is a metabolite of Montelukast.

InChI:InChI=1/C35H36ClNO4S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(42(41)23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+

Upstream product

• 158966-92-8 montelukast 
• 1250477-73-6 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]-phenyl]-3-[(prop-1-en-2-yl)phenyl]propyl]sulfinyl]methyl]-cyclopropaneacetic acid 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 1197414-05-3 C₂₉H₂₆ClNO 
• 869066-93-3 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl acetate 
• 1197374-10-9 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propan-1-ol hydrochloride 
• 1197374-06-3 montelukast 1-methyl-3-phenylpropyl amine salt 
• 1197374-12-1 [1-[(R)-1-(3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]-phenyl)-3-(2-isopropenylphenyl)propylsulfanylmethyl]cyclopropyl]acetic acid dicyclohexylamine salt 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1197374-11-0 (S)-1-(3-((E)-2-(7-chloroquinolin?2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl methanesulphonate 
• 918972-54-0 [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-[1-(1-methyl)ethenyl]phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 

Relevant articles and documents

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.

SPECIFIC IMPURITIES OF MONTELUKAST

The subject-matter of the invention consists in a method of removing specific impurities of montelukast of formula (I), which occur due to chemical instability of the target substance and also contaminate the substance in the preparation process. Further, methods of isolation of specific impurities of montelukast defined by formulae (V-A), (IV-A), (XIIIa-A), (XIIIb-A) and analytic methods used for the control of the production of montelukast in the pharmaceutical quality.